Merck reports 5% Q2 sales growth and raises 2026 revenue outlook

Merck reported second-quarter 2026 sales of $16.6 billion, up 5% from a year earlier, led by KEYTRUDA/KEYTRUDA QLEX sales of $8.4 billion and WINREVAIR sales of $588 million; Animal Health sales rose 8% to $1.8 billion. Merck posted a GAAP loss of $0.54 per share and a non-GAAP loss of $0.13, largely reflecting a $2.31-per-share charge related to its completed $6.8 billion acquisition of Terns Pharmaceuticals, and raised its 2026 sales outlook to $66.3 billion-$67.3 billion while forecasting non-GAAP EPS of $2.66-$2.76.